Five Novel Mutations in F13B Gene Resulting in FXIII Deficiency.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2150-2150
Author(s):  
Vytautas Ivaskevicius ◽  
Hannelore Rott ◽  
Inge Scharrer ◽  
Manuela Krause ◽  
Erhard Seifried ◽  
...  

Abstract Introduction. FXIII deficiency is a rare autosomal recessive disorder affecting approximatly 1 out of 1–3 million inhabitans. The disease is characterized by bleeding, impaired wound repair and spontaneous abortions in females. Extracellular FXIII molecule has a tetramer structure composing of two catalytic A-subunits and two B-subunits that act as a carrier molecules. Based on genotype there are two types of FXIII deficiency: A-subunit deficiency (XIIIA) when mutations affect F13A gene and much rarely B-subunit deficiency (XIIIB) when mutations affect F13B gene. Both types result in absence of FXIII catalytical activity in plasma. To date, only five families with isolated B-subunit deficiency have been described in the literature. Here we report five novel mutations, affecting F13B gene and resulting in FXIII deficiency. Materials and Methods. FXIII activity was measured by photometric assay according to Fickenscher et al. (1991). Fiveteen exons of F13A gene as well as 12 exons of F13B gene and their flanking regions were amplified by PCR. Sequencing was performed on an automated sequencing system. Results and Discussion. Five german origin patients with mildly reduced FXIII deficiency have been routinely investigated in order to identify genetic defects within F13A and F13B genes. All patients have shown single heterozygous mutations in F13B gene, revealing two missense, one deletion, one insertion, and one splice site mutation. There were no genetic defects in F13A gene. Patient E.M. (female, born 1947, FXIII activity 47–53%, postoperative bleeding) had a missense mutation in exon 2 (c.73 T>C, Cys5Arg) resulting in disruption of disulfide bond between amino acids Cys5 and Cys56. Patient H.D. (male, born 1983, FXIII activity 54%, epistaxis) showed a missense mutation in exon 3 (c.406C>T, Leu116Phe). It may cause instability of disulfide bond between neighbouring Cys117 and Cys71 in the second domain. Patient E.R. (female, born 1989, FXIII activity 53%, increased bleeding during menstruation) was heterozygous for an in-frame deletion (c.471–473delATT) resulting in deletion of Leu138. Patient O.S. (female, born 1983, FXIII activity 46–57%, bleeding after tonsillectomy) had a small insertion (c.1959insT) in the exon 12 changing the distal amino acid (634–641) sequence and predisposing a synthesis of additional 21 new amino acids at the Carboxy-termini of FXIIIB-Subunit due to disruption of Stop codon at position 641. Patient P.G. (male, born 1974, FXIII activity 43%, bleeding after tooth extraction) was heterozygous for a splice site mutation in intron 3 (IVS3-1 G>C). Interestingly this patient turned out also to have a mild von Willebrand Syndrome (FVIII activity 76%, vWF:RiCo 48%, vWF:Ag 56%, vWF-Collagen-Binding activity 0.54, AB0 blood group A). In conclusion, our results suggest higher prevalence of FXIIIB deficiency as it was thought before, Patients having mild (heterozygous) FXIIIB deficiency may bleed upon provocations.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1125-1125
Author(s):  
Vytautas Ivaskevicius ◽  
Arijit Biswas ◽  
Anne Thomas ◽  
Ramin Tehranchi ◽  
Johannes Oldenburg

Abstract Abstract 1125 Background and Objectives: Congenital Factor XIII (FXIII) deficiency is a rare, autosomal recessive bleeding disorder, with a significant majority of patients showing defects in the FXIII-A subunit. The disease is caused by a variety of F13A1 gene mutations resulting in a severe quantitative FXIII-A type I deficiency. Here, we report a wide spectrum of mutations identified in 41 severe Factor XIII-A deficiency patients (≥6 years of age, mean, 26.4; range, 7–60). Patients and Methods: A total of 41 patients were recruited in a multinational (23 centers, 11 countries), open-label, single-arm, phase 3, prophylaxis trial for the evaluation of the efficacy and safety of a novel recombinant FXIII (rFXIII). Eleven of the 41 patients (Israel [n=8], Switzerland [n=2] and Italy [n=1]) already had established genetic backgrounds and carried previously reported F13A1 mutations. Mutational screening in the remaining 30 patients who had unknown genetic status was done using direct sequencing on an ABI Prism 3130TL (Applied Biosystems, Weiterstadt, Germany). For two patients with splice-site mutations, cDNA analysis was done with RT-PCR (Quiagen One-step RT-PCR kit). The crystallographic model of the recombinant human cellular coagulation FXIIIA zymogen (EC: 2.3.2.13, resolution solved to 2.1Å) was downloaded from the Protein Data Bank (data file 1F13) for viewing, analysis and graphical rendering using YASARAver11.11.2. Classic molecular dynamic simulation approaches were used on the FXIII-A crystal structure to evaluate the effect of the novel missense mutations on protein structure. Results and Discussion: In total, 31 distinct mutations in 41 patients have been identified revealing 13 missense mutations, seven small deletions, six splice-site mutations, three nonsense mutations, one large deletion and one small insertion. Amongst this cohort of mutations, 16 mutations were novel. In one patient, a heterozygous missense mutation was detected in spite of severe deficiency symptoms shown by the patient. We assume that the other mutation could not be detected within the scope of our screening set up. The IVS5–1G>A (c.691–1G>A) splice-site mutation was the most commonly occurring (n=9 [21.9%]) mutation in this cohort. Two siblings carried a missense mutation in F13A1 gene (Ser295Arg) and in combination with a novel variant in F13B gene (Ser634Phe). This variant does not seem to significantly affect the B-subunit stability, since it is located in the terminal part of the molecule. Missense mutations are of special interest since they help to better understand the structure and function of FXIII A-subunit. The MD simulation of four novel missense mutations predicted a damaging effect on the protein structure for three of the missense mutations (Glu229Arg, Leu275Phe, and Arg703Trp) based on changes in bonding patterns, free energy calculations, change in local secondary structure etc. The Leu588Gln located on the surface of barrel 1 domain was not observed to cause a significant change in local structure, nevertheless, owing to its surface presentation it might influence the interaction with FXIII B-subunit. The analysis for the two novel splice-site mutations (IVS7+1G>A, IVS12+1G>A) did not show any aberrant mRNA product. Inhibitor development is the most undesirable side-effect of treatment with plasma-derived or rFXIII products. Overall, the incidence of inhibitors in patients with congenital FXIII deficiency is unknown, but is expected to be much lower compared with other coagulopathies, e.g. hemophilia A. In the present study, none of the patients treated with rFXIII (a mean treatment period of 322 days) developed FXIII neutralizing antibodies. Four patients developed transient low-titer anti-rFXIII antibodies that had no neutralizing activity. Interestingly, two patients (male and female) were siblings carrying the same common splice-site mutation in intron 5 (IVS5-1 G>A). The third patient was compound heterozygous for two missense mutations (Gln229Arg; Ser413Leu). The fourth patient was also found to be compound heterozygous for two missense mutations (Arg77His; Leu275Phe). Conclusion: To conclude, the identified mutations, including 16 novel mutations, are implicated in the causality of severe FXIII deficiency. However, none of these mutations were associated with the development of inhibitory antibodies in the context of treatment with rFXIII. Disclosures: Tehranchi: Novo Nordisk: Employment, Equity Ownership. Oldenburg:Biogen Idec, Swedish Orphan Biovitrum: Honoraria; Baxter, Bayer, Biotest, CSL Behring, Grifols, Inspiration, Novo Nordisk, Octapharma, Pfizer: Honoraria, Research Funding.


2007 ◽  
Vol 97 (06) ◽  
pp. 914-921 ◽  
Author(s):  
Rainer Seitz ◽  
Hans Kohler ◽  
Verena Schroeder ◽  
Laszlo Muszbek ◽  
Robert Ariens ◽  
...  

SummaryFXIII deficiency is known as one of the rarest blood coagulation disorders. In this study, the phenotypic and in part genotypic data of 104 FXIII-deficient patients recorded from 1993 – 2005 are presented. The most common bleeding symptoms were subcutaneous bleeding (57%) followed by delayed umbilical cord bleeding (56%), muscle hematoma (49%), hemorrhage after surgery (40%), hemarthrosis (36%), and intracerebral bleeding (34%). Prophylactic treatment was initiated in about 70% of all patients. FXIII-B subunit-deficient patients had a milder phenotype than patients with FXIII-A subunit deficiency. The most frequent mutation affecting the F13A gene was a splice site mutation in intron 5 (IVS5–1G>A). This mutation was found in eight (17%) of 46 analyzed families. The haplotype analysis of patients carrying the IVS5–1A allele was consistent with a founder effect. The international registry (http://www.f13-database.de) will provide clinicians and scientists working on FXIII deficiency with a helpful tool to improve patient care and direct future studies towards better understanding and treatment of the disease.


2018 ◽  
Vol 4 (3) ◽  
pp. e237 ◽  
Author(s):  
Kang Zhang ◽  
Qing Liu ◽  
Keqiang Liu ◽  
Dongchao Shen ◽  
Hongfei Tai ◽  
...  

ObjectiveTo investigate the genetic contribution of ANXA11, a gene associated with amyotrophic lateral sclerosis (ALS), in Chinese ALS patients with and without cognitive dementia.MethodsSequencing all the coding exons of ANXA11 and intron-exon boundaries in 18 familial amyotrophic lateral sclerosis (FALS), 353 unrelated sporadic amyotrophic lateral sclerosis (SALS), and 12 Chinese patients with ALS-frontotemporal lobar dementia (ALS-FTD). The transcripts in peripheral blood generated from a splicing mutation were examined by reverse transcriptase PCR.ResultsWe identified 6 nonsynonymous heterozygous mutations (5 novel and 1 recurrent), 1 splice site mutation, and 1 deletion of 10 amino acids (not accounted in the mutant frequency) in 11 unrelated patients, accounting for a mutant frequency of 5.6% (1/18) in FALS, 2.3% (8/353) in SALS, and 8.3% (1/12) in ALS-FTD. The deletion of 10 amino acids was detected in 1 clinically undetermined male with an ALS family history who had atrophy in hand muscles and myotonic discharges revealed by EMG. The novel p. P36R mutation was identified in 1 FALS index, 1 patient with SALS, and 1 ALS-FTD. The splicing mutation (c.174-2A>G) caused in-frame skipping of the entire exon 6. The rest missense mutations including p.D40G, p.V128M, p.S229R, p.R302C and p.G491R were found in 6 unrelated patients with SALS.ConclusionsThe ANXA11 gene is one of the most frequently mutated genes in Chinese patients with SALS. A canonical splice site mutation leading to skipping of the entire exon 6 further supports the loss-of-function mechanism. In addition, the study findings further expand the ANXA11 phenotype, first highlighting its pathogenic role in ALS-FTD.


2017 ◽  
Vol 48 (S 01) ◽  
pp. S1-S45
Author(s):  
O. Schwartz ◽  
J. Althaus ◽  
B. Fiedler ◽  
K. Heß ◽  
W. Paulus ◽  
...  

2018 ◽  
Vol 70 (5) ◽  
Author(s):  
Melahat M. Oguz ◽  
Meltem Akcaboy ◽  
Asuman Gurkan ◽  
Esma Altinel Acoglu ◽  
Pelin Zorlu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document